NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

NEW YORK — Gut microbiome health startup 32 Biosciences said on Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products.

NEW YORK – University of Chicago spinout OrisDx said Tuesday that it has raised $4 million in seed funding and it will use the money to support the launch of its saliva-based molecular test for oral ...

NEW YORK – Quest Diagnostics said Tuesday that it is collaborating with the University of Texas MD Anderson Cancer Center to develop and validate a laboratory-developed test to identify individuals ...

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.